1
/
of
1
Camber Pharmaceutical Inc
Erlonib (Erlotinib)
Erlonib (Erlotinib)
Regular price
$42,000.00 USD
Regular price
Sale price
$42,000.00 USD
Shipping calculated at checkout.
Quantity
Couldn't load pickup availability
Erlotinib is an oral tyrosine kinase inhibitor (TKI) that selectively targets the epidermal growth factor receptor (EGFR), a key protein driving cancer cell growth and survival. By blocking EGFR signaling pathways, erlotinib prevents tumor cell proliferation, enhances apoptosis, and reduces the risk of metastasis. Unlike traditional chemotherapy, this targeted therapy works by inhibiting specific molecular pathways active in cancer cells, potentially offering improved efficacy with a different side effect profile.
Erlotinib is primarily indicated for non-small cell lung cancer (NSCLC), particularly in patients with EGFR-sensitizing mutations such as exon 19 deletions or exon 21 L858R substitution. It is used as first-line monotherapy in these mutation-positive patients and as a second-line or later treatment option in patients with locally advanced or metastatic NSCLC who have progressed on prior chemotherapy regimens. Erlotinib is also approved for pancreatic cancer, where it is administered in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic disease, demonstrating survival benefits in this aggressive malignancy.
Erlotinib requires careful patient selection and ongoing monitoring. It is contraindicated in patients with known hypersensitivity to erlotinib or its components and is not recommended during pregnancy or breastfeeding due to the risk of fetal harm. Caution is essential in patients with severe hepatic impairment, as erlotinib undergoes hepatic metabolism and hepatotoxicity is a documented risk. Patients with a history of interstitial lung disease (ILD) require careful evaluation, as erlotinib carries a risk of drug-induced pulmonary toxicity, which though rare, can be severe or fatal. Additionally, patients with active gastrointestinal disorders should be monitored closely due to the potential for GI perforation.
Dosage and administration must be determined by your healthcare provider based on individual patient factors, tumor characteristics, renal and hepatic function, and concurrent medications. This medication should only be used under direct medical supervision and prescription. Do not initiate, modify, or discontinue erlotinib without consulting your physician. Regular monitoring for efficacy and adverse effects is essential during treatment.
Erlotinib is primarily indicated for non-small cell lung cancer (NSCLC), particularly in patients with EGFR-sensitizing mutations such as exon 19 deletions or exon 21 L858R substitution. It is used as first-line monotherapy in these mutation-positive patients and as a second-line or later treatment option in patients with locally advanced or metastatic NSCLC who have progressed on prior chemotherapy regimens. Erlotinib is also approved for pancreatic cancer, where it is administered in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic disease, demonstrating survival benefits in this aggressive malignancy.
Erlotinib requires careful patient selection and ongoing monitoring. It is contraindicated in patients with known hypersensitivity to erlotinib or its components and is not recommended during pregnancy or breastfeeding due to the risk of fetal harm. Caution is essential in patients with severe hepatic impairment, as erlotinib undergoes hepatic metabolism and hepatotoxicity is a documented risk. Patients with a history of interstitial lung disease (ILD) require careful evaluation, as erlotinib carries a risk of drug-induced pulmonary toxicity, which though rare, can be severe or fatal. Additionally, patients with active gastrointestinal disorders should be monitored closely due to the potential for GI perforation.
Dosage and administration must be determined by your healthcare provider based on individual patient factors, tumor characteristics, renal and hepatic function, and concurrent medications. This medication should only be used under direct medical supervision and prescription. Do not initiate, modify, or discontinue erlotinib without consulting your physician. Regular monitoring for efficacy and adverse effects is essential during treatment.
Share
